Trial · NCT03401671
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Lanadelumab | Japanese | 21.91 | Geometric Coefficient of Variation 38 | microgram per milliliter (ug/mL) | |
| Maximum Observed Plasma Concentration (Cmax) of Lanadelumab | Non-Hispanic Caucasians | 21.42 | Geometric Coefficient of Variation 25 | microgram per milliliter (ug/mL) | |
| Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of Lanadelumab | Japanese | 5.67 | Full Range 2.00 to 6.11 | day | |
| Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of Lanadelumab | Non-Hispanic Caucasians | 5.00 | Full Range 3.00 to 13.00 | day | |
| Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab | Japanese | 510.6 | Geometric Coefficient of Variation 30 | day*microgram per milliliter(day*ug/mL) | |
| Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab | Non-Hispanic Caucasians | 547.6 | Geometric Coefficient of Variation 20 | day*microgram per milliliter(day*ug/mL) | |
| Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Lanadelumab | Japanese | 515.0 | Geometric Coefficient of Variation 30 | day*microgram per milliliter(day* ug/mL) | |
| Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Lanadelumab | Non-Hispanic Caucasians | 552.7 | Geometric Coefficient of Variation 20 | day*microgram per milliliter(day* ug/mL) | |
| Terminal Elimination Rate Constant (Lambda z) for Lanadelumab | Japanese | 0.04470 | Geometric Coefficient of Variation 9 | per day | |
| Terminal Elimination Rate Constant (Lambda z) for Lanadelumab | Non-Hispanic Caucasians | 0.04385 | Geometric Coefficient of Variation 11 | per day | |
| Terminal Half-life (t12) of Lanadelumab | Japanese | 15.54 | Full Range 12.8 to 17.9 | day | |
| Terminal Half-life (t12) of Lanadelumab | Non-Hispanic Caucasians | 15.59 | Full Range 12.4 to 19.1 | day | |
| Apparent Clearance (CL/F) of Lanadelumab | Japanese | 0.5826 | Geometric Coefficient of Variation 30 | liter per day | |
| Apparent Clearance (CL/F) of Lanadelumab | Non-Hispanic Caucasians | 0.5428 | Geometric Coefficient of Variation 20 | liter per day | |
| Apparent Volume of Distribution (Vz/F) of Lanadelumab | Japanese | 13.03 | Geometric Coefficient of Variation 29 | liter | |
| Apparent Volume of Distribution (Vz/F) of Lanadelumab | Non-Hispanic Caucasians | 12.38 | Geometric Coefficient of Variation 22 | liter | |
| Body-weight Adjusted Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab | Japanese | 510.6 | Geometric Coefficient of Variation 30 | day*ug/mL/kg | |
| Body-weight Adjusted Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab | Non-Hispanic Caucasians | 547.6 | Geometric Coefficient of Variation 20 | day*ug/mL/kg | |
| Body-weight Adjusted Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) in Plasma of Lanadelumab | Japanese | 8.012 | Geometric Coefficient of Variation 44 | day*ug/mL/kg | |
| Body-weight Adjusted Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) in Plasma of Lanadelumab | Non-Hispanic Caucasians | 7.950 | Geometric Coefficient of Variation 27 | day*ug/mL/kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03401671/results